MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure

Carla Boccaccio, Paolo M. Comoglio

Research output: Contribution to journalArticle

Abstract

The MET oncogene, encoding the hepatocyte growth factor receptor, drives invasive growth, a genetic program largely overlapping with epithelial-mesenchymal transition, and governing physiological and pathological processes such as tissue development and regeneration, as well as cancer dissemination. Recent studies show that MET enables cells to overcome damages inflicted by cancer anti-proliferative targeted therapies, radiotherapy or anti-angiogenic agents. After exposure to such therapies, clones of MET-amplified cancer cells arise within the context of genetically heterogeneous tumors and.. exploiting an ample platform of signaling pathways.. drive recurrence. In cancer stem cells, not only amplification, but also MET physiological expression, inherited from the cell of origin (a stem/progenitor), can contribute to tumorigenesis and therapeutic resistance, by sustaining the inherent self-renewing, self-preserving and invasive growth phenotype.

Original languageEnglish
Pages (from-to)98-105
Number of pages8
JournalCurrent Opinion in Cell Biology
Volume31
DOIs
Publication statusPublished - Dec 1 2014

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Fingerprint Dive into the research topics of 'MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure'. Together they form a unique fingerprint.

  • Cite this